(RTTNews) - Johnson & Johnson (JNJ) announced new longer-term follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating RYBREVANT (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET. The study assessed RYBREVANT in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.
Results demonstrated that more than 70 percent of patients in the first-line subgroup responded to treatment with amivantamab plus chemotherapy, with most responses lasting beyond 16 months. These findings highlight the potential of RYBREVANT to deliver durable benefit in a difficult-to-treat patient population.
Notably, encouraging responses were also observed in patients with liver metastases, a group that typically faces poorer outcomes with colorectal cancer. The study further showed low rates of treatment-related discontinuations, underscoring the tolerability of the regimen.
The promising anti-tumor activity and durability of responses support continued investigation of RYBREVANT in ongoing Phase 3 studies for both first- and second-line colorectal cancer treatment.
Johnson & Johnson closed trading on January 9 at $204.39, down $1.36 or 0.66% during regular market hours. In after-hours trading, the stock edged higher to $204.98, gaining $0.59 or 0.29%.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
